Recently major efforts in Alzheimer's disease (AD) research have concentrated on the search for disease-associated biomarkers that can identify people at risk for developing AD, help with early diagnosis, prognosis or therapeutic decision-making, and allow for an expedited evaluation of novel disease-modifying therapies. The current project will use an advanced automated hippocampal segmentation approach based on an adaptive machine-learning algorithm paired with the hippocampal radial atrophy mapping technique to establish the dynamic pattern of hippocampal changes that occur in Alzheimer's disease in 3D. AdaBoost is a widely recognized breakthrough computer vision approach that shows great promise as an objective, reproducible and reliable automated hippocampal segmentation technique. While implementing cutting edge mathematical and statistical concepts, the combined technique provides high throughput and sensitivity to disease-associated hippocampal changes. The main goal of this project is to test the performance, variability, robustness and reproducibility of the approach in very large 1.5T and 3T epidemiological and 1.5T clinical trial datasets and to ultimately establish the AdaBoost/radial atrophy methodology as a potential secondary/surrogate outcome measure for clinical trials in AD and MCI that will overcome many of the limitations imposed by the widely used cognitive batteries such as ceiling and floor effects, fluctuations and learning and practice effects. In addition we will identify the hippocampal morphological changes associated with imminent conversion from MCI to AD and investigate potential cognitive and laboratory biomarker correlations with hippocampal atrophy thus investigating potential disease biosignatures.
If no cure is found, AD will affect as many as 10-16 million Americans by year 2050. Recently major efforts in AD research have concentrated on the search for biomarkers that can identify people at risk as early as possible and assess promising disease-modifying therapies presently being evaluated. The proposed research will further validate and establish a state-of-the-art high throughput automated imaging biomarker for use in epidemiological and clinical trial research.
|Jutkowitz, Eric; MacLehose, Richard F; Gaugler, Joseph E et al. (2017) Risk Factors Associated With Cognitive, Functional, and Behavioral Trajectories of Newly Diagnosed Dementia Patients. J Gerontol A Biol Sci Med Sci 72:251-258|
|Sokolow, Sophie; Li, Xiaohui; Chen, Lucia et al. (2017) Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment. J Alzheimers Dis 56:229-237|
|Ringman, John M; Casado, Maria; Van Berlo, Victoria et al. (2017) A novel PSEN1 (S230N) mutation causing early-onset Alzheimer's Disease associated with prosopagnosia, hoarding, and Parkinsonism. Neurosci Lett 657:11-15|
|Jefferson-George, Kyra S; Wolk, David A; Lee, Edward B et al. (2017) Cognitive decline associated with pathological burden in primary age-related tauopathy. Alzheimers Dement 13:1048-1053|
|Katsumata, Yuriko; Nelson, Peter T; Ellingson, Sally R et al. (2017) Gene-based association study of genes linked to hippocampal sclerosis of aging neuropathology: GRN, TMEM106B, ABCC9, and KCNMB2. Neurobiol Aging 53:193.e17-193.e25|
|Ringman, John M (2017) Update on Alzheimer's and the Dementias: Introduction. Neurol Clin 35:171-174|
|Qian, Jing; Hyman, Bradley T; Betensky, Rebecca A (2017) Neurofibrillary Tangle Stage and the Rate of Progression of Alzheimer Symptoms: Modeling Using an Autopsy Cohort and Application to Clinical Trial Design. JAMA Neurol 74:540-548|
|Chang, Timothy S; Teng, Edmond; Elashoff, David et al. (2017) Optimizing Effect Sizes With Imaging Enrichment and Outcome Choices for Mild Alzheimer Disease Clinical Trials. Alzheimer Dis Assoc Disord 31:19-26|
|Blanken, Anna E; Hurtz, Sona; Zarow, Chris et al. (2017) Associations between hippocampal morphometry and neuropathologic markers of Alzheimer's disease using 7 T MRI. Neuroimage Clin 15:56-61|
|Kim, Julia; Schweizer, Tom A; Fischer, Corinne E et al. (2017) The Role of Cerebrovascular Disease on Cognitive and Functional Status and Psychosis in Severe Alzheimer's Disease. J Alzheimers Dis 55:381-389|
Showing the most recent 10 out of 704 publications